SML2257
IBR2
≥98% (HPLC)
别名:
(1R)-1,2-Dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]isoquinoline, (R)-2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline, Isoquinoline, 1,2-dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]-, (1R)-
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=S(N1[C@@H](C2=CNC3=C2C=CC=C3)C4=CC=CC=C4C=C1)(CC5=CC=CC=C5)=O
InChI key
YCOHEPDJLXZVBZ-XMMPIXPASA-N
Biochem/physiol Actions
IBR2 is a cell penetrant, potent and specific RAD51 inhibitor that inhibits RAD51-mediated DNA double-strand break repair and enhances cytotoxicity of multiple anticancer agents with disparate biochemical targets including the Bcr-Abl inhibitor imatinib and multiple kinase inhibitor regorafenib. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, inhibits cancer cell growth and induces apoptosis.
cell penetrant, potent and specific RAD51 inhibitor
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Jiewen Zhu et al.
European journal of medicinal chemistry, 96, 196-208 (2015-04-16)
RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Jiewen Zhu et al.
EMBO molecular medicine, 5(3), 353-365 (2013-01-24)
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and
Peter J Ferguson et al.
The Journal of pharmacology and experimental therapeutics, 364(1), 46-54 (2017-10-25)
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors of DNA repair. To exploit this potential Achilles heel, we
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2257-25MG | 04061835504893 |
| SML2257-5MG | 04061835504909 |